Treatment of Cancer-Associated Thrombosis: Distinguishing Among Antithrombotic Agents

Seminars in Oncology

Volumn 33, Issue SUPPL. 4, 2006, Pages 26-39

  Pruemer, Jane ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BUSULFAN; DALTEPARIN; DEXTRAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE; TINZAPARIN; WARFARIN;

ALOPECIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG DELIVERY SYSTEM; DRUG SAFETY; EOSINOPHILIA; GOOD CLINICAL PRACTICE; HEALTH CARE PERSONNEL; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; MENSTRUATION; OSTEOPENIA; OSTEOPOROSIS; OUTPATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SATISFACTION; PHARMACIST; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SKIN MANIFESTATION; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TISSUE NECROSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS; ECONOMICS, PHARMACEUTICAL; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PATIENT SELECTION; PHARMACISTS; PRACTICE GUIDELINES; PROGNOSIS; RISK FACTORS; SURVIVAL; THROMBOSIS; WARFARIN;

EID: 33646069932     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.01.021     Document Type: Article

References (112)

1. Erdman S.M., Chuck S.K., and Rodvold K.A. Thromboembolic disorders. In: DiPiro J.T., Talbert R.L., and Yee G.C. (Eds). Pharmacotherapy. A Pathophysiological Approach (2000), Appleton & Lange, Stamford, CT 295-326
2. Hirsh J., Hoak J., Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), and American Heart Association. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Circulation 93 (1996) 2212-2245
3. Heinmoller E., Weinel R.J., Heidtmann H.H., et al. Studies on tumor cell-induced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol 122 (1996) 735-744
4. Tohgo A., Tanaka N.G., and Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. Effects of cell surface modification on thrombin generation, platelet aggregation and subsequent lung colonization. Invasion Metastasis 6 (1986) 58-68
5. Zhang Y., Deng Y., Luther T., et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94 (1994) 1320-1327
6. Levine M., and Rickles F.R. Treatment of venous thromboembolism in cancer patients. Haemostasis 28 suppl 3 (1998) 66-70
7. Spence R.A., Watt P.C., and Sloan J.M. Pathology for Surgeons (1993), Butterworth-Heinemann, Oxford UK
8. Anderson Jr. F.A., and Spencer F.A. Risk factors for venous thromboembolism. Circulation 107 suppl 1 (2003) I9-I16
9. Geerts W.H., Heit J.A., Clagett G.P., et al. Prevention of venous thromboembolism. Chest 119 suppl 1 (2001) 132S-175S
10. Rosendaal F.R. Venous thrombosis. A multi-causal disease. Lancet 353 (1999) 1167-1173
11. Lee A.Y.Y., and Levine M.N. Venous thromboembolism and cancer. Risks and outcomes. Circulation 107 suppl 1 (2003) I17-I21
12. Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999) 285-291
13. Heit J.A., Silverstein M.D., Mohr D.N., et al. Risk factors for deep vein thrombosis and pulmonary embolism. A population-based case-control study. Arch Intern Med 160 (2000) 809-815
14. Goodnough L.T., Saito H., Manni A., et al., A study of 159 patients. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. Cancer 54 (1984) 1264-1268
15. Dimopoulos M.A., and Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117 (2004) 508-515
16. Jacobson G.M., Kamath R.S., Smith B.J., et al. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol 96 (2005) 470-474
17. Castaman G., Rodeghiero F., and Dini E. Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. Hematologica 75 (1990) 567-599
18. Brisse H., Orbach D., Lassau N., et al. Portal vein thrombosis during antineoplastic chemotherapy in children. Report of five cases and review of the literature. Eur J Cancer 40 (2004) 2659-2666
19. Blom J.W., Doggen C.J.M., Osanto S., et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
20. Prandoni P., Lensing A.W.A., Piccioli, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. ??. Blood 100 (2002) 3484-3488
21. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) 401S-428S
22. Khushal A., Quinlan D., Alikhan R., et al. Thromboembolic disease in surgery for malignancy-Rationale for prolonged thromboprophylaxis. Semin Thromb Hemost 28 (2002) 569-576
23. Andersson L.-O., Barrowcliffe T.W., Holmer E., et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 5 (1979) 531-541
24. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 16 suppl (1990) 12-18
25. Johnson E.A., and Mulloy B. The molecular weight range of commercial heparin preparations. Carbohydr Res 51 (1976) 119-127
26. Lam L.H., Silbert J.E., and Rosenberg R.D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69 (1976) 570-577
27. Andersson L.O., Barrowcliffe T.W., Holmer E., et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 9 (1976) 575-583
28. Eika C. Inhibition of thrombin-induced aggregation of human platelets in heparin. Scand J Hematol 8 (1971) 216-222
29. Kelton J.G., and Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 17 (1980) 259-291
30. Fernandez F., Nguyen P., Van Ryn J., et al. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 43 (1986) 491-495
31. Blajchman M.A., Young E., and Ofosu F.A. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 556 (1989) 245-254
32. Ockelford P.A., Carter C.J., Cerskus A., et al. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction. Thromb Res 27 (1982) 679-690
33. Clowes A.W., and Karnovsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265 (1977) 625-626
34. Shaughnessy S.G., Young E., Deschamps P., et al. The effects of low molecular weight and standard heparin on calcium loss from the fetal rat calvaria. Blood 86 (1995) 1368-1373
35. Bhandari M., Hirsh J., Weitz J., et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 80 (1998) 413-417
36. Castellot J.J., Favreau L.V., Karnovsky M.J., et al. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem 257 (1982) 11256-11260
37. Rosenberg R.D., and Bauer K.A. The heparin-antithrombin system. A natural anticoagulant mechanism. In: Colman R.W., Hirsch J., Marder V.J., et al. (Eds). Hemostasis and Thrombosis. Basic Principles and Clinical Practice. (Ed 3). (1994), Lippincott, Philadelphia, PA 837-860
38. Danielsson A., Raub E., Lindahl U., et al. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 261 (1986) 15467-15473
39. Jordan R.E., Oosta G.M., Gardner W.T., et al. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 255 (1980) 10081-10090
40. Hirsh J., Warkentin T.E., et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 suppl (2001) 64S-94S
41. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
42. Sandset P.M., Bendz B., and Hansen J.B. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 30 suppl 2 (2000) 48-56
43. Fareed J. Basic and applied pharmacology of low molecular weight heparins. Pharmacol Ther suppl (1995) 16S-24S
44. Ray K.K., Francis S., and Crossman D.C. A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes. The role of interleukin-1 receptor antagonist genotype. J Thromb Haemost 3 (2005) 287-291
45. Montalescot G., Bal-dit-Sollier C., Chibedi D., et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 91 (2003) 925-930
46. Fareed J., Ma Q., Florian M., et al. Differentiation of low-molecular-weight heparins. Impact on the future of the management of thrombosis. Semin Thromb Hemost 30 suppl 1 (2004) 89-104
47. Zacharski L.R., and Ornstein D.L. Heparin and cancer. Thromb Haemost 80 (1998) 10-23
48. Handeland G.F., Abildgaard U., Holm H.A., et al. Dose adjusted heparin treatment of deep venous thrombosis. A comparison of unfractionated heparin and low molecular weight heparin. Eur J Clin Pharmacol 39 (1990) 107-112
49. Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 (1996) 677-681
50. O'Brien B., Levine M., Willan A., et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 159 (1999) 2298-2304
51. Spyropoulos A.C., Kardos J., and Wigal P. Outcomes analyses of the outpatient treatment of venous thromboembolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization. J Managed Care Pharm 6 (2000) 298-304
52. Warkentin T.E., Levine M.N., Hirsch J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
53. LaPointe K.J., Cappuzzo K.A., and Hamilton C.W. Low-molecular-weight heparins for deep vein thrombosis. US Pharmacist HS3-HS23 (2001)
54. Greinacher A., and Warkentin T.E. Treatment of heparin-induced thrombocytopenia. An Overview. In: Warkentin T.E., and Greinacher E. (Eds). Heparin-Induced Thrombocytopenia. (Ed 2) (2001), Marcel Dekker, New York, NY 291-322
55. Turpie A.G.G. Can we differentiate the low-molecular-weight heparins?. Clin Cardiol 23 suppl 1 (2000) 14-17
56. Hyers T.M., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease. Chest 119 suppl 1 (2001) 176S-193S
57. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 311-337
58. Bick R.L., Frenkel E.P., Walenga J., et al. Unfractionated heparin, low molecular weight heparins, and pentasaccharide. Basic mechanisms of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am 19 (2005) 1-51
59. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
60. Andrea N., and Ansell J. Management of thrombosis in the cancer patient. J Supportive Oncol 1 (2003) 235-245
61. Levine M.N., Gent M., Hirsch J., et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch Intern Med 156 (1996) 851-856
62. Koopman M.M.W., Prandoni P., Piovella F., et al., The Tasman Study Group. Treatment of venous thromboembolism with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 334 (1996) 682-687
63. Coumadin (warfarin sodium) Prescribing Information (2002), Bristol-Myers Squibb Company, New York, NY
64. Ridker P.M. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation. Rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med 3 (1998) 67-73
65. Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348 (2003) 1425-1434
66. Kearon C. Long-term management of patients after venous thromboembolism. Circulation 110 suppl 1 (2004) I10-I18
67. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) 338S-400S
68. Cohen A., Davidson B., Gallus A., et al. Fondaparinux for the prevention of VTE in acutely ill medical patients. Blood 102 (2003) 15 abstr 42
69. Hull R.D., Raskob G.E., Pineo G.F., et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326 (1992) 975-982
70. de Valk H.W., Banga J.D., Wester J.W., et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Int Med 123 (1995) 1-9
71. Leizorovicz A., Simonneau G., Decousus H., et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis. A meta-analysis. BMJ 309 (1994) 299-304
72. Lensing A.W., Prins M.H., Davidson B.L., et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 155 (1995) 601-607
73. Nurmohamed M.T., Verhaeghe R., Haas S., et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 169 (1995) 567-571
74. Dolovich L., Ginsberg J.S., Douketis J., et al. A meta-analysis comparing low molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 160 (2000) 181-188
75. Agnelli G., Bergqvist D., Cohen A., et al. A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery. The Pegasus study. J Thrombos Haemost 1 suppl 1 (2003) abstr OC006
76. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery. A double-blind randomized multicentre trial with venographic assessment. Br J Surg 84 (1997) 1099-1103
77. Bergqvist D., Agnelli G., Cohen A.T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
78. Levine M., Hirsh J., Gent M., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994) 886-889
79. Siragusa S., Cosmi B., Piovella F., et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism. Results of a meta-analysis. Am J Med 100 (1996) 269-277
80. Gould M.K., Dembitzer A.D., Doyle R.L., et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130 (1999) 800-809
81. Prandoni P., Piccioli A., and Girolami A. Cancer and venous thromboembolism. An overview. Haematologica 84 (1999) 437-445
82. Iorio A., Guercini F., Conti S., et al. Low molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism. Meta-analysis of the randomized comparisons with oral anti-coagulants. J Thromb Haemost 1 suppl 1 (2003) abstr P1873
83. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for secondary prevention of venous thromboembolism in patients with cancer. A randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
84. Monreal M., Zacharski L., Jimenez A., et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer. A prospective cohort study. J Thromb Haemost 2 (2004) 1311-1315
85. Green D., Hull R.D., Brant R., et al. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339 (1992) 1476
86. Kakkar A.K., Levine M.N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer. The Fragmin Advanced Malignancy OUtcome Study (FAMOUS). J Clin Oncol 22 (2004) 1944-1948
87. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271
88. Conti S., Guercini F., and Iorio A. Low-molecular-weight heparin and cancer survival. Review of the literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiol Haemost Thromb 33 (2003) 197-201
89. Klerk C.P.W., Smorenburg S.M., Otten H.-M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 10 (2005) 2130-2135
90. Lee A.Y.Y., Rickles F.R., Julian J.A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005) 2123-2129
91. Hull R., Pineo G.F., Mah A.F., et al. (LITE Investigators). A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer. J Thromb Haemost 1 suppl 1 (2003) abstr P1373a
92. Seo P., and Locke C.F. Current and potential uses of low molecular weight heparin. A review and an economic analysis. Am J Managed Care 6 (2000) 498-506
93. Spyropoulos A.C. Outpatient-based treatment protocols in the management of venous thromboembolic disease. Am J Managed Care 6 suppl 20 (2000) S1034-S1044
94. Rutschmann O.T., and Matchar D.B. Economics of low-molecular weight heparins. Am J Managed Care 6 suppl 20 (2000) S1054-S1065
95. Wade W.E., Martin B.C., Kotzan J.A., et al. Formulary management of low molecular weight heparins. Pharmacoeconomics 17 (2000) 1-12
96. Hull R.D., Pineo G.F., and Raskob G.E. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin. Outcome of therapy and health economy aspects. Haemostasis 28 suppl 3 (1998) 8-16
97. Vichiendilokkul A. Breaking out of the silo. One health system's experience. Am J Health Syst Pharm 59 suppl 6 (2002) S15-S17
98. Gould M.K., Dembitzer A.D., Sanders G.D., et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 130 (1999) 789-799
99. Groce III J., and Cooper Jr. J.W. The pharmacoeconomics of low molecular-weight heparins. Getting the most bang for the health care buck. Consult Pharm 16 suppl D (2001) 18-22
100. Spandorfer J.M., Lynch S., Weitz H.H., et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 84 (1999) 478-480
101. Smith L., McKee B.D., and Schroeder D.P. Cost effectiveness and safety of outpatient bridge therapy. Chest 116 suppl 2 (1999) 360S abstr
102. Spyropoulos A.C., Frost F.J., Hurley J.S., et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 125 (2004) 1642-1650
103. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the use of low-molecular-weight heparins for adult outpatients treatment of acute deep-vein thrombosis. Am J Health Syst Pharm 61 (2004) 1950-1955
104. Nightingale S.L. From the Food and Drug Administration. JAMA 270 (1993) 1672
105. Hirsh J., Guyatt G., Albers G.W., et al. The Seventh ACCP Consensus Conference on Antithrombotic Therapy. Chest 126 (2004) 163S-696S
106. Fareed J., Hoppensteadt D., Schultz C., et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des 10 (2004) 983-999
107. Fareed J., Leong W., Hoppensteadt D.A., et al. Development of generic low molecular weight heparins. A perspective. Hematol Oncol Clin North Am 19 (2005) 53-68
108. McCart G.M., and Kayser S.R. Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother 36 (2002) 1042-1057
109. Wells P.S., Anderson D.R., Marc A.R., et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 165 (2005) 733-738
110. Falanga A., and Zacharski L. Deep vein thrombosis in cancer. The scale of the problem and approaches to management. Ann Oncol 16 (2005) 696-701
111. Schumock G.T., Nutescu E.A., and Walton S.M. Survey of hospital policies regarding low-molecular-weight heparins. Am J Health Syst Pharm 59 (2002) 534-538
112. Groce III J., and Cooper Jr. J.W. DVT/pulmonary embolism prophylaxis in medically ill patients. A new avenue of clinical management in the long-term care setting. Consult Pharm 16 suppl D (2001) 7-17